StreetInsider.com News Articles

Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Wed, 02 Sep 2026 16:30:00 -0400

WALTHAM, Mass., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing masked immuno-oncology therapies for people living with cancer, today announced that, effective September 1, 2026, the company granted non-qualified stock options to purchase 19,865 shares of its common stock to two new employees under Xilio Therapeutics’ 2022 Inducement Stock Incentive Plan.

The stock options have an exercise price of $8.88 per share, which is equal to the closing price of the company’s common stock on September 1, 2026. Each stock option has a ten-year term

Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Wed, 02 Sep 2026 16:30:00 -0400

The stock options have an exercise price of $8.88 per share, which is equal to the closing price of the company’s common stock on September 1, 2026. Each stock option has a ten-year term

Form SCHEDULE 13G/A Xilio Therapeutics, Inc. Filed by: STEMPOINT CAPITAL LP

Fri, 14 Aug 2026 12:01:00 -0400

si-local-file:///var/storage/secattach/20260814/26927526.html

Form SCHEDULE 13G/A Xilio Therapeutics, Inc. Filed by: STEMPOINT CAPITAL LP

Fri, 14 Aug 2026 12:01:00 -0400

si-local-file:///var/storage/secattach/20260814/26927526.html

Xilio Therapeutics, Inc. (XLO) Tops Q2 EPS by 25c

Wed, 12 Aug 2026 07:48:41 -0400

Xilio Therapeutics, Inc. (NASDAQ: XLO) reported Q2 EPS of ($0.33), $0.25 better than the analyst estimate of ($0.58). Revenue for the quarter came in at $18.7 million versus the consensus estimate of $7.27 million.

For earnings history and earnings-related data on Xilio Therapeutics, Inc. (XLO) click here.

Form S-8 Xilio Therapeutics, Inc.

Wed, 12 Aug 2026 07:46:00 -0400

si-local-file:///var/storage/secattach/20260812/26909013.html

Form S-8 Xilio Therapeutics, Inc.

Wed, 12 Aug 2026 07:46:00 -0400

si-local-file:///var/storage/secattach/20260812/26909013.html

Form 10-Q Xilio Therapeutics, Inc. For: Jun 30

Wed, 12 Aug 2026 07:41:00 -0400

si-local-file:///var/storage/secattach/20260812/26908991.html

Form 10-Q Xilio Therapeutics, Inc. For: Jun 30

Wed, 12 Aug 2026 07:41:00 -0400

si-local-file:///var/storage/secattach/20260812/26908991.html

Form 8-K Xilio Therapeutics, Inc. For: Aug 12

Wed, 12 Aug 2026 07:35:00 -0400

si-local-file:///var/storage/secattach/20260812/26908975.html

Form 8-K Xilio Therapeutics, Inc. For: Aug 12

Wed, 12 Aug 2026 07:35:00 -0400

si-local-file:///var/storage/secattach/20260812/26908975.html

Xilio Therapeutics Reports Second Quarter 2026 Financial Results and Provides Pipeline and Business Updates

Wed, 12 Aug 2026 07:30:00 -0400

Received FDA clearance of IND application for XTX501, a potential best-in-class bispecific PD-1 / masked IL-2

Advancing IND-enabling studies for potential first-in-class multi-specific, masked T cell engager programs targeting CLDN18.2 and PSMA+STEAP1; IND applications anticipated in the second half of 2027

Cash runway into the first quarter of 2028 expected to support key milestones across pipeline of next generation multi-specific I-O therapies

WALTHAM, Mass., Aug. 12, 2026 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing masked immuno-oncology therapies for people living with cancer, today

Xilio Therapeutics Reports Second Quarter 2026 Financial Results and Provides Pipeline and Business Updates

Wed, 12 Aug 2026 07:30:00 -0400

Received FDA clearance of IND application for XTX501, a potential best-in-class bispecific PD-1 / masked IL-2

Cash runway into the first quarter of 2028 expected to support key milestones across pipeline of next generation multi-specific I-O therapies

Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Mon, 06 Jul 2026 16:30:00 -0400

WALTHAM, Mass., July 06, 2026 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing masked immuno-oncology therapies for people living with cancer, today announced that, effective July 1, 2026, the company granted non-qualified stock options to purchase 107,060 shares of its common stock to three new employees under Xilio Therapeutics’ 2022 Inducement Stock Incentive Plan.

The stock options have an exercise price of $9.22 per share, which is equal to the closing price of the company’s common stock on July 1, 2026. Each stock option has a ten-year term

Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Mon, 06 Jul 2026 16:30:00 -0400

The stock options have an exercise price of $9.22 per share, which is equal to the closing price of the company’s common stock on July 1, 2026. Each stock option has a ten-year term

Xilio Therapeutics names Ben Harshbarger as chief legal officer

Mon, 29 Jun 2026 07:30:10 -0400

Xilio Therapeutics, Inc. (Nasdaq: XLO) has appointed Ben Harshbarger as chief legal officer, the clinical-stage biotechnology company announced.

Harshbarger brings more than 20 years of legal and executive experience in the biopharmaceutical industry. He most recently served as chief legal officer at Astria Therapeutics, Inc. until its acquisition by BioCryst Pharmaceuticals, Inc. At Astria, he was involved in the company's rebranding from Catabasis Pharmaceuticals, Inc., its development from a pre-clinical to a late-stage clinical organization, and its eventual acquisition.

Before Astria, Harshbarger served as interim chief executive officer and general counsel at Novelion Therapeutics Inc., and as general counsel at Aegerion Pharmaceuticals,

Xilio Therapeutics Appoints Ben Harshbarger as Chief Legal Officer

Mon, 29 Jun 2026 07:30:00 -0400

WALTHAM, Mass., June 29, 2026 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing masked immuno-oncology therapies for people living with cancer, today announced the appointment of Ben Harshbarger as chief legal officer.

“Ben is a proven leader, with deep legal and strategic experience across all stages of biotechnology companies,” said René Russo, Pharm.D., president and chief executive officer of Xilio. “He joins our leadership team at an important time at Xilio, as we advance our pipeline of next-generation, multi-specific I-O therapies toward the clinic, including XTX501, a potential

Xilio Therapeutics Appoints Ben Harshbarger as Chief Legal Officer

Mon, 29 Jun 2026 07:30:00 -0400

Form 4 Xilio Therapeutics, Inc. For: Jun 11 Filed by: Bonstein Sara